Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul J. Sekhri
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Beta
- 0.28
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 3.37
Financials
Revenue
$0.00-100.0%Net Income
$-13.05MEBITDA
$-13.05MFree Cash Flow
$-11.44MEPS (diluted)
$-1.05Shares Outstanding (diluted)
12.41M+5021.8%Operating Expenses
$13.93MCash & Debt
$86.64MReturn of Capital
$0.00Revenue by Segment (annual)
$1.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-26.97M | $-3.20 |
| 2024 | $1.02M | $-18.46M | $-3.20 |
| 2023 | $0.00 | $-20.25M | $-9.71 |
| 2022 | $2.02M | $-19.16M | $-9.98 |
| 2021 | $4.00M | $-12.99M | $-8.29 |
| 2020 | $6.41M | $-8.50M | $-7.21 |
| 2019 | $2.76M | $-21.94M | $-28.97 |
| 2018 | $12.43M | $-7.91M | $-25.42 |
| 2017 | $291.0K | $-16.14M | $-66.62 |
| 2016 | $634.0K | $-16.35M | $-68.52 |
| 2015 | $519.0K | $-27.50M | $-132.90 |
| 2014 | $1.55M | $-36.10M | $-173.87 |
| 2013 | $976.0K | $-48.20M | $-234.57 |
Valuation
VTVThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160+220.00%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·6h ago·Positive
vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program Transcript vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program Transcript
View source ↗ - Newsmarketbeat.com·8h ago·Neutral
vTv Therapeutics Highlights Cadisegliatin's Phase III Push to Tackle Type 1 Hypoglycemia vTv Therapeutics NASDAQ: VTVT used a virtual key opinion leader event to outline the continuing burden of hypoglycemia in type 1 diabetes, present patient and physician market-research findings, and review the development program for its investigational oral therapy, cadisegliatin.
View source ↗ - Newsglobenewswire.com·13d ago·Negative
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin
View source ↗ - Newsglobenewswire.com·15d ago·Neutral
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) Milestone advances Phase 3 program toward topline results expected in mid 2027 Milestone advances Phase 3 program toward topline results expected in mid 2027
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-1.07 per share
Typical surprise -5.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-1.05 vs $-0.97miss
- Wed, May 13$1.65 vs $0.34beat
- Tue, Mar 10$-0.58 vs $-0.98beat
- Thu, Nov 6$-1.08 vs $-0.97miss
- Tue, Aug 12$-0.92 vs $-0.85miss
- Thu, May 15$-0.77 vs $-0.73miss
Estimates and results for VTVT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VTVT officers and directors.
- Bought
- $135k
- Sold
- —
5 trades
0 trades
- Sekhri Paul Jbought
- Sekhri Paul Jbought
- Sekhri Paul Jbought
- Fry John Abought
- Fry John Abought
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VTVT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.